open access

Vol 23, No 6 (2018)
Special Issue Papers
Published online: 2018-11-01
Submitted: 2018-04-23
Get Citation

Neoadjuvant chemotherapy in woman with early or locally advanced cervical cancer

Marcela de la Torre
DOI: 10.1016/j.rpor.2018.09.005
·
Rep Pract Oncol Radiother 2018;23(6):528-532.

open access

Vol 23, No 6 (2018)
Special Issue Papers
Published online: 2018-11-01
Submitted: 2018-04-23

Abstract

Cervical cancer is a major global health problem for women. Despite the screening and vaccines available today, it continues to be the fourth most common cancer in women worldwide with 85% of cases occurring in developing countries. Standard treatments for early or locally advanced cervical cancer are surgery (S) or concomitant chemo-radiotherapy (CT-RT). Neoadjuvant chemotherapy (NACT) prior to surgery or radiotherapy has been proposed and tested in clinical trials and has been included in clinical practice in some countries.

In order to determine the true role of NACT either prior to S or RT in terms of achieving benefits in OS or DFS, randomized clinical trials and meta-analyses published from its beginnings to the present have been searched and analyzed in this study.

The analysis of published clinical trials shows that NACT followed by S and NACT followed by RT have failed to demonstrate benefits in OS or DFS. Clinical trials comparing NACT followed by S versus exclusive RT have also been analyzed, where NACT followed by S could not show benefits for RT either.

Conclusion

Adding neoadjuvant chemotherapy to S or RT cannot be recommended outside the context of clinical trials.

Abstract

Cervical cancer is a major global health problem for women. Despite the screening and vaccines available today, it continues to be the fourth most common cancer in women worldwide with 85% of cases occurring in developing countries. Standard treatments for early or locally advanced cervical cancer are surgery (S) or concomitant chemo-radiotherapy (CT-RT). Neoadjuvant chemotherapy (NACT) prior to surgery or radiotherapy has been proposed and tested in clinical trials and has been included in clinical practice in some countries.

In order to determine the true role of NACT either prior to S or RT in terms of achieving benefits in OS or DFS, randomized clinical trials and meta-analyses published from its beginnings to the present have been searched and analyzed in this study.

The analysis of published clinical trials shows that NACT followed by S and NACT followed by RT have failed to demonstrate benefits in OS or DFS. Clinical trials comparing NACT followed by S versus exclusive RT have also been analyzed, where NACT followed by S could not show benefits for RT either.

Conclusion

Adding neoadjuvant chemotherapy to S or RT cannot be recommended outside the context of clinical trials.

Get Citation

Keywords

Cervical cancer; Neoadjuvant chemotherapy; Treatment

About this article
Title

Neoadjuvant chemotherapy in woman with early or locally advanced cervical cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 6 (2018)

Pages

528-532

Published online

2018-11-01

DOI

10.1016/j.rpor.2018.09.005

Bibliographic record

Rep Pract Oncol Radiother 2018;23(6):528-532.

Keywords

Cervical cancer
Neoadjuvant chemotherapy
Treatment

Authors

Marcela de la Torre

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl